Early use of higher-efficacy therapies is recommended for patients with moderately to severely active Crohn disease (CD), ...

In the video, Dr. Nicola J. Gullick, a Consultant Rheumatologist in Coventry and one of the investigators on the PRO-SPIRIT ...

Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...